Keros Therapeutics Inc (NASDAQ: KROS) kicked off on Monday, down -5.56% from the previous trading day, before settling in for the closing price of $10.79. Over the past 52 weeks, KROS has traded in a range of $9.77-$72.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 410.20% over the past five years. While this was happening, its average annual earnings per share was recorded 6.78%. With a float of $32.88 million, this company’s outstanding shares have now reached $40.55 million.
Let’s look at the performance matrix of the company that is accounted for 169 employees. In terms of profitability, gross margin is 83.58%, operating margin of -5938.96%, and the pretax margin is -5269.1%.
Keros Therapeutics Inc (KROS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Keros Therapeutics Inc is 18.93%, while institutional ownership is 77.92%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.13% during the next five years compared to -48.13% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Take a look at Keros Therapeutics Inc’s (KROS) current performance indicators. Last quarter, stock had a quick ratio of 21.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 116.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.01, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.15 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (NASDAQ: KROS) saw its 5-day average volume 0.7 million, a negative change from its year-to-date volume of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 20.31%. Additionally, its Average True Range was 0.55.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 0.77%, which indicates a significant decrease from 21.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.18% in the past 14 days, which was lower than the 215.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.15, while its 200-day Moving Average is $38.70. Nevertheless, the first resistance level for the watch stands at $10.44 in the near term. At $10.68, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.05. If the price goes on to break the first support level at $9.83, it is likely to go to the next support level at $9.46. The third support level lies at $9.22 if the price breaches the second support level.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
The company with the Market Capitalisation of 413.33 million has total of 40,562K Shares Outstanding. Its annual sales at the moment are 3,550 K in contrast with the sum of -187,350 K annual income. Company’s last quarter sales were recorded 3,040 K and last quarter income was -46,030 K.
